Nutriband：2025年季度报告

FORM10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedJuly 31, 2025 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number000-55654 NUTRIBAND INC.(Exact name of registrant as specified in its charter) (407)377-6695(Registrant’s Telephone Number, Including Area Code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ The number of shares outstanding of the issuer’s common stock, par value $0.001 per share, was12,034,883shares as of September 8,2025. NUTRIBAND INC. INDEX Page No.Part I: Financial Information1Item 1Financial Statements1Condensed Consolidated Balance Sheets as of July 31, 2025 (unaudited) and January 31, 2025.2Condensed Consolidated Statements of Operations for the three months ended July 31, 2025 and 2024(unaudited),3Consolidated Statements of Stockholders’ Equity for the three months ended July 31, 2025 and 2024(unaudited)4Condensed Consolidated Statements of Cash Flows for the three months ended July 31, 2025, and 2024(unaudited)6Notes to Unaudited Condensed Consolidated Financial Statements7Item 2Management’s Discussion and Analysis of Financial Condition and Results of Operations21Item 3Quantitative and Qualitative Disclosures about Market Risk24Item 4Controls and Procedures24Part II: Other Information25Item 1.Legal Proceedings25Item 1ARisk Factors25Item 5Other Information27Item 6Exhibits27 NUTRIBAND INC. PART I. FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS Certain information and footnote disclosures required under accounting principles generally accepted in the United States of Americahave been condensed or omitted from the following financial statements pursuant to the rules and regulations of the Securities andExchange Commission. The results of operations for the three and six months ended July 31, 2025 and 2024 are not necessarily indicative of the results for theentire fiscal year or for any other period. NUTRIBAND INC. AND SUBSIDIARIESUNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) NUTRIBAND INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (UNAUDITED) NUTRIBAND INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) NUTRIBAND INC. AND SUBSIDIARIESNotes to Unaudited Consolidated Financial Statementsas of and for the Three and Six Months Ended July 31, 2025 and 2024 1.ORGANIZATION AND DESCRIPTION OF BUSINESS Organization Nutriband Inc. (the “Company”) is a Nevada corporation, incorporated on January 4, 2016. In January 2016, the Companyacquired Nutriband Ltd, an Irish company which was formed by the Company’s chief executive officer in 2012 to enter the healthand wellness market by marketing transdermal patches. References to the Company relate to the Company and its subsidiariesunless the context indicates otherwise. On August 1, 2018, the Company acquired 4P Therapeutics LLC (“4P Therapeutics”) for $2,250,000, consisting of250,000sharesof common stock, valued at $1,850,000, and $400,000, and a royalty of6% on all revenue generated by the Company from theabuse deterrent intellectual property that had been developed by 4P Therapeutics payable to the former owner of 4P Therapeutics.The former owner of 4P Therapeutics was a director of the Company from April 2018, when the Company entered into anagreement to acquire 4P Therapeutics until he resigned as a director in January 2022. 4P Therapeutics is engaged in the development of transdermal pharmaceutica